CFM
TLX

Capricorn Fund Managers’s Telix Pharmaceuticals TLX Stock Holding History

Capricorn Fund Managers’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
+36,100
New +$368K 0.03% 160

Other funds holding TLX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Capricorn Fund Managers's TLX Position: Q2 2026 in Review

Capricorn Fund Managers opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 36,100 shares worth $416K. The stake represents 0.03% of the portfolio and ranks #160 among its holdings.

9 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Capricorn Fund Managers held 36,100 shares of Telix Pharmaceuticals worth $416K as of Q2 2026.
  • Telix Pharmaceuticals was a new Capricorn Fund Managers position in Q2 2026.
  • Telix Pharmaceuticals made up 0.03% of Capricorn Fund Managers's portfolio in Q2 2026, its #160 holding.
  • 9 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Capricorn Fund Managers's 13F filing for Q2 2026, filed 24 Jul 2026.